



# National Library of Medicine PubMed

PubMed	Nucleotide	Protein	Genome	Structure	PopSet	Taxonomy	<input checked="" type="radio"/> MIM	
Search PubMed	<input type="button" value="▼ for"/>					Go	Clear	
		Limits	Preview/Index	History	Clipboard			
		Display	Abstract	<input type="button" value="▼"/>	Save	Text	Order	Add to Clipboard

Entrez  
PubMed

1: *Blood* 1999 Feb 15;93(4):1231-6

[Related Articles](#), [Books](#), [LinkOut](#)

FREE full text article at  
[www.bloodjournal.org](http://www.bloodjournal.org)

## A histomorphometric evaluation of heparin-induced bone loss after discontinuation of heparin treatment in rats.

Shaughnessy SG, Hirsh J, Bhandari M, Muir JM, Young E, Weitz JI

Departments of Pathology and Medicine, McMaster University and the Hamilton Civic Hospitals Research Centre, Hamilton, Ontario, Canada.

PubMed  
Services

NEW  
Related  
Resources

Although it is well established that long-term heparin therapy causes osteoporosis, it is unknown whether heparin-induced bone loss is reversible when heparin treatment is stopped. To address this question, we randomized rats to once daily subcutaneous injections of either unfractionated heparin (1.0 U/g or 0.5 U/g) or saline for 28 days and then followed the rats for an additional 28 days off treatment. Based on histomorphometric analysis of the distal third of the right femur proximal to the epiphyseal growth plate, 1.0 U/g heparin caused a 30% loss in cancellous bone volume over the first 28 days. This was accompanied by a 137% increase in osteoclast surface and a 60% decrease in both osteoblast and osteoid surface. One month after cessation of heparin treatment, no recovery in these parameters was observed. Similarly, serum levels of alkaline phosphatase, a biochemical marker of bone formation, which continued to decrease over the course of heparin treatment, showed no signs of recovery in the subsequent 28 days off treatment. To explore the mechanism responsible for the prolonged effect of heparin on bone, we repeated the experiment giving <sup>125</sup>I-labeled heparin in place of unlabeled heparin. <sup>125</sup>I-labeled heparin was found to accumulate in bone during the course of its administration, and be retained in bone for at least 56 days after stopping heparin treatment. These findings suggest that heparin-induced osteoporosis is not rapidly reversible because heparin is sequestered in bone for an extended period.

PMID: 9949165, UI: 99135853

Display Abstract  Save Text Order Add to Clipboard

[Write to the Help Desk](#)